Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547063 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13737068 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL7520137 | 0.90 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12987975 | 0.89 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12987977 | 0.89 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL24359130 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19894397 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2580965 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14389708 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20732056 | 0.88 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | claimed |
| JP-2004512810-A | — | — | 2004-04-30 | — | — | JP | claimed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2001525667-A | — | — | 2001-12-11 | — | — | JP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| EP-0980424-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | claimed |
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6617438-B1 | Nucleic acid of given formula; ribozyme able to cleave RNA of HER2 gene; use as anticarcinogenic agent | SIRNA THERAPEUTICS, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-1321521-A1 | Ribozymes directed against flt-1 | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6528640-B1 | Of given formula; can use to inhibit HER2/neu/ ErbB2 gene expression; anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0980424-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1998050530-A9 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARM INC (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |